GL Partners Adds to Position in SciClone Pharmaceuticals; Reveals New Stake in China Biologic Products

GL Partners Capital Management has increased the holding of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) stock.

Keep Reading →